LENZ Therapeutics, Inc.
No SEC Form 4 filings for $LENZ in the last 30 days.
See all $LENZ insider activity →LENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991q226pressrelease.htm EX-99.1 Document Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence,
LENZ Therapeutics (Nasdaq: LENZ) said VIZZ (aceclidine ophthalmic solution) 1.44% is now available via a telehealth platform at VIZZ.com, adding online eligibility evaluation by licensed eye care providers, e-pharmacy fulfillment, and home delivery. LENZ plans to promote the channel with a national TV campaign featuring Sarah Jessica Parker.
LENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. lenz-20260630 FALSE 0001815776 Solana Beach California 0001815776 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
Over the past 7 days, alphai's AI scored 1 news story mentioning LENZ (LENZ Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LENZ coverage spans financial news, corporate actions and earnings.
The 8-K provides fresh commercial traction metrics (packs, refill behavior, prescriber uptake) plus cash and expense updates, shaping near-term sentiment and risk.
Telehealth + TV/digital DTC promotion is a new go-to-market channel that could accelerate VIZZ adoption and improve access, supporting near-term sales expectations.
Board/audit committee changes can affect governance oversight and investor sentiment, but the filing provides no financial guidance or operational change.
Routine corporate governance vote results; no new operating/financial guidance or material transaction disclosed.
LENZ Therapeutics has reported revenues below expectations and increased losses, leading analysts to cut future revenue estimates and target prices. The stock has experienced a 13% decline following these revisions. Despite the negative outlook, the company's revenue growth rate remains faster than industry peers.
alphai scores every news story that mentions LENZ with an AI model for sentiment and relevance, and aggregates insider trades from LENZ Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991q226pressrelease.htm EX-99.1 Document Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence,
6 min readLENZ Therapeutics (Nasdaq: LENZ) said VIZZ (aceclidine ophthalmic solution) 1.44% is now available via a telehealth platform at VIZZ.com, adding online eligibility evaluation by licensed eye care providers, e-pharmacy fulfillment, and home delivery. LENZ plans to promote the channel with a national TV campaign featuring Sarah Jessica Parker.
4 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. lenz-20260630 FALSE 0001815776 Solana Beach California 0001815776 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. lenz-20260612 FALSE 0001815776 Solana Beach California 0001815776 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year's revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.
3 min readWall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a "hold" to a "sell" rating. This follows a similar downgrade by Weiss Ratings, although the consensus among analysts still rates the stock as a "Moderate Buy" with an average target price of $56.40. The article also details the company's stock performance, institutional investor holdings, and company profile.
3 min readLENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min readVIZZ improved near vision in 30 mins with effects lasting up to 10 hours in Phase 3 trials. LENZ may earn over $195 million from licensing deals in Asia and Canada, plus double-digit royalties. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
4 min readDoes LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readThe consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 min read
